Skip to main content
MEDICALSYSTEM BIOTECHNOLOGY CO., LTD logo

MEDICALSYSTEM BIOTECHNOLOGY CO., LTD — Investor Relations & Filings

Ticker · 300439 ISIN · CNE100001Z25 LEI · 3003007XTAWFVR8ASC23 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,715 across all filing types
Latest filing 2022-10-11 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300439

About MEDICALSYSTEM BIOTECHNOLOGY CO., LTD

https://www.nbmksw.com

MedicalSystem Biotechnology Co., Ltd. specializes in the research, development, production, and distribution of in vitro diagnostic (IVD) products. The company offers a comprehensive portfolio that includes biochemical reagents, chemiluminescence immunoassay systems, molecular diagnostic kits, and point-of-care testing (POCT) solutions. Its product line covers a wide range of clinical applications such as liver function, kidney function, blood lipids, and cardiovascular markers. MedicalSystem is recognized for its integrated business model, which combines the manufacturing of high-quality diagnostic instruments with a vast array of compatible reagents. Additionally, the company provides third-party medical laboratory services to healthcare institutions. By focusing on technological innovation and standardized production, MedicalSystem supports clinical laboratories in achieving accurate and efficient diagnostic results for improved patient care.

Recent filings

Filing Released Lang Actions
关于公司取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acquisition of medical device registration certificates issued by the National Medical Products Administration (国家药品监督管理局). It details the registration certificate numbers, validity periods, and intended uses of the medical devices. The document also discusses the potential impact on the company's business and includes a risk warning to investors. The document is short (1135 characters) and does not contain financial statements, management discussion, or detailed financial data. It is an official announcement about regulatory approval and its business implications, not a financial report or detailed management report. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2022-10-11 Chinese
关于收到《传票》及《改期开庭通知书》暨诉讼事项的进展公告
Legal Proceedings Report Classification · 100% confidence The document is a public announcement from a company regarding the progress of a litigation case involving a shareholder dispute. It details court summons, hearing dates, case background, and the current status of the lawsuit. There are no financial statements, earnings data, or management discussion of financial results. The document is not a report but a legal proceeding update. Therefore, it fits the category of Legal Proceedings Report (LTR). The document length is short and focused solely on litigation updates, confirming it is not a full report or announcement of a report publication.
2022-09-29 Chinese
关于公司取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acquisition of medical device registration certificates issued by regulatory authorities. It includes details about the certificates, their validity, and the potential impact on the company's business and risks. The document is short (1361 characters) and does not contain financial statements or detailed financial data. It is an announcement of a regulatory approval event rather than a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-09-15 Chinese
关于公司取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acquisition of a medical device registration certificate issued by the National Medical Products Administration. It includes details about the certificate, product use, and potential impact on company performance. The document is short (968 characters) and serves as a formal notification rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or regulatory certifications. It is not an annual or interim report, nor a call transcript or governance document. The content fits best as a regulatory announcement informing investors about a material event related to product registration. Therefore, it should be classified as a Regulatory Filing (RNS).
2022-08-30 Chinese
2022年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2022 半年度报告摘要' which translates to '2022 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period, including revenue, net profit, earnings per share, and asset information. It also discusses company operations, shareholder information, and important events during the reporting period. The length of the document (5306 characters) and the presence of substantive financial data and analysis confirm it is a financial report for a period shorter than a full fiscal year. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-25 Chinese
2022年半年度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled "美康生物科技股份有限公司 2022 年半年度报告" which translates to "Medical System Biotechnology Co., Ltd. 2022 Semi-Annual Report." It covers the period from January 1, 2022 to June 30, 2022, as indicated in the definitions section. The content includes detailed financial data, management discussion and analysis, company overview, industry analysis, and other comprehensive information typical of a semi-annual or interim financial report. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. The presence of financial metrics, management discussion, and detailed operational data confirms it is a substantive financial report for a period shorter than a full fiscal year. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-25 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.